Abstract

Background: Geriatric depression with subjective memory complaints increases the risk for Alzheimer's Disease. Memantine, a neuroprotective drug, can improve depression and help prevent cognitive decline. In our 6-months clinical trial, escitalopram/memantine (ESC/MEM) improved mood and cognition compared to escitalopram/placebo treatment (ESC/PBO; NCT01902004). In this report, we investigated whether baseline brain white matter integrity in fronto-limbic-striatal tracts can predict clinical outcomes using fractional anisotropy (FA).Methods: Thirty-eight older depressed adults (mean age = 70.6, SD = 7.2) were randomized to ESC/MEM or ESC/PBO and underwent diffusion-weighted imaging (DWI) at 3 Tesla at baseline. Mood was assessed using the Hamilton Depression Rating Scale (HAMD), apathy using the Apathy Evaluation Scale (AES) and anxiety using the Hamilton Anxiety Scale (HAMA) at baseline and 6-months follow-up. FA was extracted from seven tracts of interest (six in each hemisphere and one commissural tract) associated with geriatric depression. Non-parametric General Linear Models were used to examine group differences in the association between FA and symptom improvement, controlling for age, sex, baseline symptom scores and scanner model, correcting for false discovery rate (FDR). Post-hoc tests further investigated group differences in axial, mean and radial diffusivity (AD, MD, and RD, respectively). Lastly, we performed an exploratory whole-brain model to test whether FA might be related to treatment response with memantine.Results: There were no differences in remission rates or HAMD change between groups. In bilateral anterior and posterior internal capsule tracts and bilateral inferior and right superior fronto-occipital (IFO and SFO) fasciculus, higher FA was associated with larger improvements in depressive symptoms for ESC/MEM, but not ESC/PBO, correcting for FDR. Lower MD in the left IFO and RD in the right anterior internal capsule were associated with improved treatment responses. We found no significant associations in the whole-brain analysis.Limitations: Included small sample size and high dropout.Conclusions: Higher baseline FA and lower RD and MD in hypothesized fronto-limbic-striatal tracts predicted greater improvement in mood and anxiety with ESC/MEM compared to ESC/PBO in geriatric depression. FA as a biomarker for white matter integrity may serve as a predictor of treatment response but requires confirmation in larger future studies.

Highlights

  • Depression is among the most common and disabling conditions in older adults [1,2,3,4]

  • Participants included a sub-sample of 38 older adults diagnosed with major depressive disorder (MDD) who participated in a larger clinical randomized placebo-controlled trial [RCTNCT01902004, [22]] comparing the efficacy of escitalopram and memantine (ESC/MEM) compared to escitalopram/placebo treatment (ESC/PBO) in treating geriatric depression with subjective memory complaints

  • No images were excluded for motion or other artifacts and there was no difference in baseline fractional anisotropy (FA) averaged across ROIs between Trio and Prisma scanners [left FA: x2(1) = 0.03, p = 0.87; right FA: x2(1) = 3.09, p = 0.15]

Read more

Summary

Introduction

Depression is among the most common and disabling conditions in older adults [1,2,3,4]. While 70% of depressed older adults successfully respond to the first-line antidepressant therapy with selective serotonin reuptake inhibitors (SSRIs) after 8– 12 weeks of treatment [5], only 30–40% achieve remission [6]. Geriatric depression is associated with reduced remission rates compared to younger depressed adults, which may be due to comorbid cognitive impairments with subjective memory decline and diminished executive functions [7,8,9,10]. Comorbid cognitive impairments can worsen disease prognosis and increase the risk of developing Alzheimer’s disease [11,12,13]. Geriatric depression with subjective memory complaints increases the risk for Alzheimer’s Disease. In our 6-months clinical trial, escitalopram/memantine (ESC/MEM) improved mood and cognition compared to escitalopram/placebo treatment (ESC/PBO; NCT01902004). We investigated whether baseline brain white matter integrity in fronto-limbic-striatal tracts can predict clinical outcomes using fractional anisotropy (FA)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call